Bonesupport: History, Competition & Market Size
Former Senior Sales Executive at Bonesupport
inpractise.com/articles/bonesupport-history-competition-and-market-size
Bonesupport: History, Competition & Market Size(September 3, 2024)
Former Senior Sales Executive at Bonesupport
Interview Transcript
This is a snippet of the transcript, sign up to read more.
It's only $5,000 in the US, for CERAMENT G?
And in a very average hospital like Syracuse, there's a hospital there called Community General. There are 10 orthopedic surgeons there. Five of them or four of them will use it. All of a sudden, each doctor is doing 50 kits at $5,000, giving us $250,000 per doctor. And now I have five or four doctors. Every regional hospital in some town, USA, is worth $1 million. And what do I take into the account? Nothing. No kit, no hardware, no trials, nothing. No instrumentation. Zero. Just the CERAMENT kit, which is a small box. They open it, they inject it. And furthermore, you don't need to stay there for the entire procedure. You can just be there for 30 minutes and be gone.
This is a snippet of the transcript, sign up to read more.
So the bone growth is really the big differentiator between BONESUPPORT and its competitors.
When I left, we were the top contender at the British Foot and Ankle Society meeting. Doctors would flock to us. Our dinners had 20 doctors every night, not drinking wine, but really chatting about the science and engaging with other doctors. What is the most important indication for trauma based on amputations? Who are half of all patients that get an amputation foot.
This is a snippet of the transcript, sign up to read more.
Related Content
Bonesupport: CERAMENT, Bone Infections & Use Cases
Former Sales Manager at Bonesupport
Intuitive Surgical: Da Vinci Sales & Training Process
Intuitive Surgical vs Laparoscopy Cost and Sales Process
Former VP Clinical Sales at Intuitive Surgical
Intuitive Surgical: Training Surgeons on the Da Vinci
Former VP Clinical Sales at Intuitive Surgical
Copyright Notice
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2024 IP 1 Ltd. All rights reserved.